Search Results for “Spine ” – Page 3 – media

Former J&J sales rep indicted on charges of defrauding Boston hospital

Dive Brief A former DePuy Synthes sales representative and team lead was arrested this week for allegedly defrauding a Boston area hospital and lying to federal authorities investigating whether he interfered with the hospital’s sterilization processes. Matthew Capobianco, 45, of Winchester, Massachusetts, was indicted on eight counts of wire fraud and one count of making material false statements, according to the U.S. Attorney’s Office in Boston. Johnson & Johnson unit DePuy Synthes, in an emailed statement, said all government claims against the company in the matter have been resolved. Dive Insight According to the Department of Justice indictment, Capobianco defrauded the hospital out of hundreds of thousands of dollars’ worth of spine products that he falsely represented as used in surgeries from January 2016 through June 2017. The Boston area hospital was not named in the DOJ’s statement. To boost his sales numbers and his compensation, Capobianco falsely represented on ...
- Source: drugdu
- 137
- June 30, 2023
European Commission grants two new marketing authorisations for UCB’s Bimzelx

The European Commission (EC) has granted UCB’s Bimzelx (bimekizumab) two new approvals, with the inflammatory disease drug now authorised to treat certain adults with psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA). The marketing authorisations, which follow a pair of recommendations from the European Medicines Agency’s human medicines committee earlier this year, make Bimzelx the first and only IL-17A and IL-17F inhibitor approved in the EU for these two indications. The authorisation for PsA – a type of arthritis that affects some patients with psoriasis – specifically applies to those with active disease who have had an inadequate response or have been intolerant to one or more disease-modifying antirheumatic drugs. The approval was supported by results from two phase 3 trials in which Bimzelx showed improvements over placebo in joint and skin symptoms across biologic naïve and TNF inhibitor-inadequate responder populations. “The approval of [Bimzelx] in PsA provides rheumatologists and dermatologists ...
- Source: drugdu
- 111
- June 12, 2023
analysts

Dive Brief: Growth in parts of the orthopedic market will start to normalize late this year as surgeons work though a backlog of cases that had been postponed by the COVID-19 pandemic, analysts at Needham wrote. The analysts expect hip growth to normalize late this year and the knee and spine markets to slow down by the end of 2024. In the trauma and extremities market, the analysts see potential for “above-normal growth for some time.” A slowdown in capital spending by hospitals, currency fluctuations and supply chain issues are among factors the analysts said could hurt revenue for a number of the orthopedic companies. Dive Insight: Orthopedic companies have made a fast start to 2023, with Zimmer Biomet’s CEO saying “pretty much everything went better than expected” in the first quarter and an analyst admitting to being “kind of blown away by how good the growth rates were in ...
- Source: drugdu
- 159
- May 25, 2023
Quest to Reach Another Segment in Liquid Biopsy with New M&A

Omar Ford Quest Diagnostics is diving into a quickly growing segment of liquid biopsy with its latest M&A prospect. The Secaucus, NJ-based company announced a definitive agreement to acquire Haystack Oncology in an all-cash equity transaction. Quest will pay $300 million in cash at closing and Haystack has the potential to obtain up to an additional $150 million in performance milestones. If the deal were to close, then Quest would inherit Baltimore, MD – based Haystack’s minimal residual disease testing technology. MRD testing is a specific category of liquid biopsy that identifies circulating tumor DNA (ctDNA) in the bloodstream of patients following surgery and treatment for cancer. In a prospective, multi-institution study published in the New England Journal of Medicine in June 2022, an earlier version of the Haystack technology demonstrated the ability to better identify patients with residual disease for adjuvant chemotherapy after surgery for stage II colon cancer, thereby reducing ...
- Source: drugdu
- 137
- May 1, 2023
Making young mice old in a matter of three weeks

In a paper recently published in PNAS Nexus, researchers from the Department of Comparative Biosciences at the University of Illinois Urbana-Champaign describe how they were able to inhibit the activity of a specific neuronal cell type in the hippocampus to induce cellular and behavioral changes associated with aging. Their study confirms a causal relationship between reduced function of certain interneurons in the brain and cognitive decline. In addition, their novel experimental model may be useful for studying age-related cognitive disorders. First author Jinrui Lyu, a graduate student in the Neuroscience Program and the Department of Comparative Biosciences, performed and analyzed the experiments for the study. Corresponding author Uwe Rudolph is professor and head of the Department of Comparative Biosciences in the College of Veterinary Medicine. These authors answered some questions about the design and significance of their study. What was the motivation for your study? Our lab is interested in why ...
- Source: drugdu
- 120
- April 29, 2023
Baxter’s new Actifuse Flow bone graft alternative gets FDA nod.

Actifuse Flow, Baxter International’s new synthetic bone graft surrogate from its osteobiologics surgery series, wins FDA approval for implementation in orthopedic surgeries. In order to reach tine bony cracks and gaps of the skeletal structure, the new bone graft alternative is designed to reach these exact cranny locations. It is delivered via a syringe already containing it to speed-up bone growth. No preparatory procedure or mixing is needed to use this bone graft substitute and it maintains its fluid consistency during the surgery. The surgical products manufacturer’s Actifuse Bone Graft Alternative constituting Actifuse Flow implements the silicate-substituted technology for bone formation via raised levels of silicon. It becomes an ideal candidate for minimally invasive surgical procedures as the syringe facilitates the start and stop of flow to deliver the precise amount of substance. This also enables it to compact small done deformities as well as the intricate disorder of bone ...
- Source: drugdu
- 1,069
- September 13, 2018
Shenzhen Chuanggan – Health Assessment Facility Supplier

Healthcare assessment facilities are defined as places providing personalized care, where health needs are identified by conducting routine general examinations after which a systematic plan will be delivered accordingly by skilled physicians or nurses.
- Source: Ddu
- 1,383
- September 4, 2018
Healthcare assessment facilities Researches
Who Requires Physical Rehabilitation Therapy?

After a serious injury or surgery, there is always a specific amount of time needed to recover. During this period, varied resources are needed to regain the strength of doing things independently. In hospitals, the continuous availability of physiotherapists will help in rehabilitation therapy.
- Source: Ddu
- 771
- August 28, 2018
physical therapy physiotherapy Researches
4 Operating Tables and Their Features

Finding the right operating table for your hospital can be stressful with many factors to consider. The right one benefits not only patients but also surgeons, making surgical procedures and examinations simpler. Ddu (www.drugdu.com) the leading global pharmaceutical and medical devices B2B platform offers a variety of operating tables for sale to meet your needs.
- Source: Ddu
- 976
- August 14, 2018
Market Views surgery
Woman’s Bone Vanished into Thin Air!

A woman aged 44 years old continuous pain in her left arm and shoulder. The doctors at the Royal Infirmary of Edinburgh in Scotland were unable to figure out the causative factor. Upon taking X-rays, they were astounded to find that the bones were disappearing. The woman was diagnosed with vanishing bone disease (Gorham-Stout disease).
- Source: LiveScience
- 742
- July 12, 2018
bone rare diseases Researches

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.